

## PRESS RELEASE

# EAHAD 2022 Congress – Latest Clinical Trial Results session

**Brussels, Belgium, 20 January 2022** - The 15<sup>th</sup> Congress of the European Association for Haemophilia and Allied Disorders is taking place from 2 to 4 February 2022. Under the direction of the Organising Committee, the EAHAD 2022 Virtual Congress aims to continue being a locus for the latest innovations and advances in the field of haemophilia and bleeding disorders.

On Friday 4 February, the Latest Clinical Trial Results session will take place. Chaired by EAHAD President, Prof. Flora Peyvandi, and covering the latest developments in our field, the session will host six not-to-be-missed presentations:

- Prof. Wolfgang Miesbach will open the session with his presentation on *“Final analysis from the pivotal phase 3 HOPE-B Gene Therapy trial: Stable steady-state efficacy and Safety of etranacogene dezaparvovec in adults with severe or moderately severe haemophilia B”*.
- Dr Robert Klamroth will follow with *“Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Haemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Haemophilia A or B Without Inhibitors (ATLAS-A/B)”*.
- Trevor Baglin will present on *“Serpinc1 is well-tolerated and reduces bleeding in persons with severe haemophilia (PwH) in a 24 week repeat dose study - AP-0101 - Ph2a”*.
- Prof. Johannes Oldenburg will have a presentation on *“Cases of decreased FVIII activity (FVIII:C) in previously treated patients (PTP) during post-marketing surveillance of N8-GP”*.
- Prof. Oldenburg will also present on *“Emicizumab prophylaxis in people with mild or moderate haemophilia A without factor VIII inhibitors: Results from the Interim Analysis of the HAVEN 6 Study”*.
- Prof. Johnny Mahlangu will close the session presenting on *“Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe haemophilia A: Results from the GENE8-1 two-year analysis”*.

With such high-level presentations, the session will offer a deep dive into key issues that have the potential to transform the future haemophilia and allied disorders landscape and spark joint reflection and in-depth discussions.

We look forward to seeing you online at [EAHAD 2022](https://www.eahad.org/2022), from 2 to 4 February 2022.

## About EAHAD:

The European Association for Haemophilia and Allied Disorders (EAHAD) is a multidisciplinary association of healthcare professionals who provide care for individuals with haemophilia and other bleeding disorders. Its members include haematologists, internists, paediatricians, nurses, physiotherapists, psychosocial professionals, laboratory scientists, and researchers from across Europe.

Since its establishment in 2007, EAHAD has worked to improve the situation of people living with haemophilia and other bleeding disorders. For more information, visit: [www.eahad.org](http://www.eahad.org).

For more information, please contact: Angelos Athanasopoulos, EAHAD Communications and Events Manager, +32 485 86 1683, [angelos.athan@eahad.org](mailto:angelos.athan@eahad.org)

###